vs
Celldex Therapeutics, Inc.（CLDX）与IMMUCELL CORP（ICCC）财务数据对比。点击上方公司名可切换其他公司
IMMUCELL CORP的季度营收约是Celldex Therapeutics, Inc.的45.9倍（$5.5M vs $120.0K）。IMMUCELL CORP净利率更高（-2.5% vs -67764.2%，领先67761.6%）。IMMUCELL CORP同比增速更快（-8.4% vs -89.8%）。IMMUCELL CORP自由现金流更多（$-1.8M vs $-65.2M）。过去两年IMMUCELL CORP的营收复合增速更高（3.9% vs -12.3%）
Celldex Therapeutics是一家临床阶段生物制药企业，专注于开发针对难治性癌症和罕见免疫疾病的靶向免疫疗法，管线涵盖抗体药物偶联物、单克隆抗体等创新疗法，致力于满足大量未被满足的临床医疗需求。
ImmuCell Corp是一家总部位于美国的动物健康生物技术企业，主要研发、生产和销售以奶牛为主的家畜相关保健与治疗产品，核心产品包括乳腺炎等常见牛类疾病的防治方案，主要服务北美地区的畜牧养殖户和兽医机构。
CLDX vs ICCC — 直观对比
营收规模更大
ICCC
是对方的45.9倍
$120.0K
营收增速更快
ICCC
高出81.4%
-89.8%
净利率更高
ICCC
高出67761.6%
-67764.2%
自由现金流更多
ICCC
多$63.4M
$-65.2M
两年增速更快
ICCC
近两年复合增速
-12.3%
损益表 — Q4 2025 vs Q3 2025
| 指标 | | |
|---|---|---|
| 营收 | $120.0K | $5.5M |
| 净利润 | $-81.3M | $-139.7K |
| 毛利率 | — | 42.9% |
| 营业利润率 | -72628.3% | 0.4% |
| 净利率 | -67764.2% | -2.5% |
| 营收同比 | -89.8% | -8.4% |
| 净利润同比 | -72.7% | 80.1% |
| 每股收益（稀释后） | $-1.23 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLDXICCC
| Q4 25 | $120.0K | — | ||
| Q3 25 | $0 | $5.5M | ||
| Q2 25 | $730.0K | $6.4M | ||
| Q1 25 | $695.0K | $8.1M | ||
| Q4 24 | $1.2M | $7.8M | ||
| Q3 24 | $3.2M | $6.0M | ||
| Q2 24 | $2.5M | $5.5M | ||
| Q1 24 | $156.0K | $7.3M |
净利润CLDXICCC
| Q4 25 | $-81.3M | — | ||
| Q3 25 | $-67.0M | $-139.7K | ||
| Q2 25 | $-56.6M | $501.9K | ||
| Q1 25 | $-53.8M | $1.4M | ||
| Q4 24 | $-47.1M | — | ||
| Q3 24 | $-42.1M | $-701.7K | ||
| Q2 24 | $-35.8M | $-1.5M | ||
| Q1 24 | $-32.8M | $-437.9K |
毛利率CLDXICCC
| Q4 25 | — | — | ||
| Q3 25 | — | 42.9% | ||
| Q2 25 | — | 43.7% | ||
| Q1 25 | — | 41.6% | ||
| Q4 24 | — | 36.5% | ||
| Q3 24 | — | 26.3% | ||
| Q2 24 | — | 22.5% | ||
| Q1 24 | — | 31.6% |
营业利润率CLDXICCC
| Q4 25 | -72628.3% | — | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | -8747.5% | 8.8% | ||
| Q1 25 | -9027.2% | 13.9% | ||
| Q4 24 | -4768.3% | 8.0% | ||
| Q3 24 | -1633.5% | -9.6% | ||
| Q2 24 | -1854.2% | -25.3% | ||
| Q1 24 | -26030.8% | -4.1% |
净利率CLDXICCC
| Q4 25 | -67764.2% | — | ||
| Q3 25 | — | -2.5% | ||
| Q2 25 | -7753.4% | 7.8% | ||
| Q1 25 | -7740.4% | 17.9% | ||
| Q4 24 | -4007.8% | — | ||
| Q3 24 | -1320.0% | -11.7% | ||
| Q2 24 | -1434.8% | -28.0% | ||
| Q1 24 | -21030.8% | -6.0% |
每股收益（稀释后）CLDXICCC
| Q4 25 | $-1.23 | — | ||
| Q3 25 | $-1.01 | $-0.02 | ||
| Q2 25 | $-0.85 | $0.06 | ||
| Q1 25 | $-0.81 | $0.16 | ||
| Q4 24 | $-0.71 | $0.09 | ||
| Q3 24 | $-0.64 | $-0.09 | ||
| Q2 24 | $-0.54 | $-0.20 | ||
| Q1 24 | $-0.56 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $518.6M | $3.9M |
| 总债务越低越好 | — | $9.5M |
| 股东权益账面价值 | $527.2M | $29.8M |
| 总资产 | $583.0M | $45.7M |
| 负债/权益比越低杠杆越低 | — | 0.32× |
8季度趋势，按日历期对齐
现金及短期投资CLDXICCC
| Q4 25 | $518.6M | — | ||
| Q3 25 | $583.2M | $3.9M | ||
| Q2 25 | $630.3M | — | ||
| Q1 25 | $673.3M | — | ||
| Q4 24 | $725.3M | $3.8M | ||
| Q3 24 | $756.0M | — | ||
| Q2 24 | $802.3M | $1.3M | ||
| Q1 24 | $823.8M | $960.3K |
总债务CLDXICCC
| Q4 25 | — | — | ||
| Q3 25 | — | $9.5M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $8.7M | ||
| Q4 24 | — | $9.0M | ||
| Q3 24 | — | $9.4M | ||
| Q2 24 | — | $9.8M | ||
| Q1 24 | — | $10.2M |
股东权益CLDXICCC
| Q4 25 | $527.2M | — | ||
| Q3 25 | $598.4M | $29.8M | ||
| Q2 25 | $655.4M | $29.9M | ||
| Q1 25 | $703.0M | $29.0M | ||
| Q4 24 | $747.0M | $27.5M | ||
| Q3 24 | $785.9M | $26.4M | ||
| Q2 24 | $813.7M | $23.5M | ||
| Q1 24 | $838.6M | $24.6M |
总资产CLDXICCC
| Q4 25 | $583.0M | — | ||
| Q3 25 | $648.4M | $45.7M | ||
| Q2 25 | $692.4M | $46.7M | ||
| Q1 25 | $739.5M | $45.6M | ||
| Q4 24 | $792.3M | $45.1M | ||
| Q3 24 | $823.2M | $44.4M | ||
| Q2 24 | $845.6M | $41.9M | ||
| Q1 24 | $868.8M | $43.1M |
负债/权益比CLDXICCC
| Q4 25 | — | — | ||
| Q3 25 | — | 0.32× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | 0.33× | ||
| Q3 24 | — | 0.36× | ||
| Q2 24 | — | 0.42× | ||
| Q1 24 | — | 0.41× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-63.9M | $-1.2M |
| 自由现金流经营现金流 - 资本支出 | $-65.2M | $-1.8M |
| 自由现金流率自由现金流/营收 | -54350.8% | -32.3% |
| 资本支出强度资本支出/营收 | 1067.5% | 10.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-213.7M | $715.4K |
8季度趋势，按日历期对齐
经营现金流CLDXICCC
| Q4 25 | $-63.9M | — | ||
| Q3 25 | $-48.6M | $-1.2M | ||
| Q2 25 | $-44.0M | $1.6M | ||
| Q1 25 | $-54.4M | $1.6M | ||
| Q4 24 | $-32.5M | $-3.1K | ||
| Q3 24 | $-55.3M | $-639.3K | ||
| Q2 24 | $-29.3M | $581.8K | ||
| Q1 24 | $-40.6M | $418.5K |
自由现金流CLDXICCC
| Q4 25 | $-65.2M | — | ||
| Q3 25 | $-49.1M | $-1.8M | ||
| Q2 25 | $-44.7M | $1.4M | ||
| Q1 25 | $-54.6M | $1.2M | ||
| Q4 24 | $-33.2M | $-199.3K | ||
| Q3 24 | $-55.9M | $-727.7K | ||
| Q2 24 | $-29.6M | $471.0K | ||
| Q1 24 | $-41.0M | $348.1K |
自由现金流率CLDXICCC
| Q4 25 | -54350.8% | — | ||
| Q3 25 | — | -32.3% | ||
| Q2 25 | -6127.8% | 22.4% | ||
| Q1 25 | -7861.4% | 15.4% | ||
| Q4 24 | -2828.3% | -2.6% | ||
| Q3 24 | -1751.2% | -12.1% | ||
| Q2 24 | -1185.0% | 8.6% | ||
| Q1 24 | -26270.5% | 4.8% |
资本支出强度CLDXICCC
| Q4 25 | 1067.5% | — | ||
| Q3 25 | — | 10.8% | ||
| Q2 25 | 99.7% | 2.4% | ||
| Q1 25 | 38.1% | 4.1% | ||
| Q4 24 | 64.3% | 2.5% | ||
| Q3 24 | 17.1% | 1.5% | ||
| Q2 24 | 11.0% | 2.0% | ||
| Q1 24 | 220.5% | 1.0% |
现金转化率CLDXICCC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 3.19× | ||
| Q1 25 | — | 1.09× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
